MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression by unknown
SHORT REPORT Open Access
MMP2 and MMP7 at the invasive front of
gastric cancer are not associated with
mTOR expression
Jan Bornschein1*, Tina Seidel1, Cosima Langner1, Alexander Link1, Thomas Wex1,2, Michael Selgrad1,
Doerthe Jechorek3, Frank Meyer4, Elizabeth Bird-Lieberman5, Michael Vieth3 and Peter Malfertheiner1*
Abstract
Background: Regulation of MMP expression by activation of mTOR signalling has been demonstrated for several
tumor types, but has thus far not been confirmed in gastric cancer.
Findings: The study compromised 128 patients who underwent gastric resection for cancer (66.4 % male; 86
intestinal, 42 diffuse type). Immunohistochemical staining of MMPs was performed to analyse the topographical
pattern of MMP expression at the tumor center and the invasive front, respectively. MMP2 showed higher
expression at the invasive front compared to the tumor center, whereas MMP7 staining scores were higher in the
tumor center, and there was no difference for MMP9. The expression of p-mTOR was higher in the tumor center
than at the invasive front, with a similar trend for mTOR. For intestinal type gastric cancer there was a weak
correlation of MMP9 with expression of mTOR in the tumor center. Otherwise, there was no correlation of the
MMPs with mTOR. By treatment of MKN45 gastric cancer cells with rapamycin, a reduction of p-mTOR in the
Western blot was achieved; however, expression of MMPs remained unaffected.
Conclusions: Expression of MMP2 and MMP7 in gastric cancer is not associated with mTOR, MMP9 expression
might be related to mTOR signalling in a subset of tumors.
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Findings
The degradation of the extracellular matrix by matrix
metalloproteinases (MMPs) is essential for invasive be-
haviour of gastric cancer [1–3]. Expression of MMPs
can be induced by specific growth factors [4, 5], and de-
pending on the cellular energy level growth factor
dependent processes can be regulated by mammalian
target of rapamycin (mTOR) related signalling [6]. Thus,
also mTOR activation has a role in tumor invasion and
metastatic spread [7, 8] and, unsurprisingly, its expression
is identified in up to 64 % of gastric cancers [7–9]. The
link between growth factor dependent activation of PI3K/
Akt/mTOR signalling and downstream up-regulation of
MMP gene expression has been shown in vitro for several
cancer types [4, 10–12]. However, a direct association be-
tween mTOR activation and MMP expression has not
been shown for gastric cancer so far. MMP2, MMP7 and
MMP9 have been most extensively investigated in gastric
cancer, but never previously in a direct comparison and in
association with mTOR expression. The aim of this study
was to investigate whether the expression of MMP2,
MMP7, and MMP9 in humans is associated with the ex-
pression of mTOR in its “naïve” and its phosphorylated
(active) form in different topographical regions of gastric
adenocarcinomas. Separate assessment of the tumor cen-
ter and the invasive front of the cancer has been per-
formed to evaluate the involvement of this potential
regulatory mechanism for invasive growth of gastric
adenocarcinomas.
The clinicopathological characteristics of patients who
underwent gastrectomy for gastric cancer between 1997
and 2009 were retrospectively identified from the
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archives of the Magdeburg University Hospital (Table 1).
Patients with neoadjuvant treatment and with adenocar-
cinoma associated with Barrett’s metaplasia and/or loca-
tion proximal at the esophagogastric junction (Siewert
type 1) were excluded from the analysis. For statistical
reasons, tumors showing a mixed type according to the
Laurén classification (n = 14) or cancers with mucinous
phenotype (n = 2) were combined with the group of dif-
fuse type carcinomas (n = 26). Patients with diffuse type
gastric cancer below the age of 50 years at diagnosis or
who presented with a positive family history were
assessed for mutations of the CDH1 gene, which was
negative in all respective cases. Finally, paraffin embed-
ded tissue for immunohistochemistry (IHC) was
retrieved for 128 patients (Table 1). The study was ap-
proved by the ethics committee of our institution (Ref.
2004–98) and conducted according to the ethical guide-
lines of the declaration of Helsinki as revised in 1989. In
an additional proof-of-principle approach, we measured
the expression of MMP2, MMP7 and MMP9 in MKN45
gastric cancer cells before and after treatment with the
mTOR inhibitor rapamycin to investigate the putative
link between mTOR signalling and MMP expression in
gastric cancer. MMP expression has been assessed by
RT-PCR. The activity of mTOR signalling has been
assessed by Western blot for the main downstream tar-
get of mTOR the P70S6K which is only active in its
phosphorylated form (p-P70S6K). Please see Additional
Fig. 1 Immunohistochemical staining at the tumor center and the invasive front. Exemplary staining of MMP2, MMP7, MMP9, as well as mTOR
and p-mTOR in the tumor center, at the invasive front (100×), and subcellular expression with larger magnification (400×). Arrows are marking the
marginal zone of the tumor at the invasive front. Squares are marking the magnified area for each panel
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file 1 (supplementary methods) for further details. For
statistical comparisons, non-parametrical tests have been
applied using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
For group comparisons the Mann Whitney U-test was
used, Wilcoxon's sign rank test for matched pair com-
parison between tumor center and invasion front. For
correlation analysis Spearman’s rank correlation test was
applied. For comparison of categorical data Fisher's exact
test was applied. For all tests a two-sided significance
level of p < 0.05 was considered significant.
IHC staining reaction of the tumor was present in 44-
60 % for MMP2, MMP7, and MMP9, as well as in 96 %
and 80 % for mTOR and p-mTOR, respectively
(Additional file 2: Figure S1). As assessed by the
immune-reactivity scores [13], only MMP2 was more
markedly expressed at the invasive front, whereas
MMP9 was homogenously expressed throughout the
invasive front and the tumor center (Fig. 1, Table 2). In
contrast, MMP7 staining was more pronounced in the
tumor center relative to the invasive front. Both mTOR
and p-mTOR staining was more pronounced in the
tumor center than at the invasive front (Table 2).
The immune-reactivity scores for the expression of
mTOR and p-mTOR as well as for MMP2, MMP7, and
MMP9 in the tumor center correlated each with its ex-
pression at the invasive front (p < 0.001; Additional file
3: Figure S2a-e). Only for intestinal type tumors, there
was a correlation of mTOR with MMP9 expression both
in the tumor center (r = 0.251, p = 0.020) and at the inva-
sive front (r = 0.254, p = 0.018; Additional file 4: Figure
S3a). Otherwise, there was no association between
mTOR and MMP2 or MMP7 as assessed by the IHC
analysis. Staining of mTOR in the tumor center corre-
lated with p-mTOR (r = 0.195, p = 0.028; Additional file
4: Figure S3b), and there was a positive association
MMP2 with MMP9 at the invasive front (r = 0.214, p =
0.015; Additional file 4: Figure S3c).
mTOR (p = 0.003) and p-mTOR (p = 0.02) staining
was associated with stage of disease, with lower staining
scores in the tumor center of advanced stage cancers
Table 2 Immune-reactivity score for expression of mTOR, p-mTOR, MMP2, MMP7, MMP9 in the tumor center and at the invasive
front of type gastric cancer
Targets Intestinal type (n = 86) Diffuse type (n = 42) Overall (N = 128)
Tumor center Invasive front p-value Tumor center Invasive front p-value Tumor center Invasive front p-value
MMP2 4.10 ± 5.042 7.65 ± 7.782 <0.001* 2.93 ± 3.925 5.40 ± 6.688 0.005* 3.72 ± 4.721 6.91 ± 7.490 <0.001*
MMP7 5.43 ± 8.345 4.48 ± 7.680 0.008* 5.10 ± 8.798 4.50 ± 7.613 (0.128) 5.32 ± 8.463 4.48 ± 7.628 0.002*
MMP9 4.57 ± 7.362 3.97 ± 7.058 (0.227) 5.62 ± 7.821 4.71 ± 6.656 (0.144) 4.91 ± 7.501 4.21 ± 6.912 (0.097)
mTOR 10.95 ± 7.543 9.79 ± 8.778 0.025* 8.67 ± 6.091 9.12 ± 6.463 (0.589) 10.20 ± 7.156 9.57 ± 8.072 (0.127)
p-mTOR 3.42 ± 4.185 2.69 ± 4.610 0.008* 2.13 ± 2.662 2.76 ± 4.667 (0.545) 3.00 ± 3.792 2.71 ± 4.610 0.013*
Comparison between tumor center and invasive front has been done by the Mann–Whitney U-test with significant differences (p < 0.05) marked by an asterisk.
Values are given as mean and standard deviation
Table 1 Demographic and clinicopathological characteristics of the main study population
Parameters Intestinal (n = 86) Diffuse (n = 42) Total (N = 128) p-value
Age in years (median, IQR) 79 (72–85) 78 (68–84) 78 (70–78) 0.239
Sex (male) 61 (70.9 %) 24 (57.1 %) 85 (66.4 %) 0.163
T-stage T1 13 (15.1 %) 3 (7.1 %) 16 (12.5 %) 0.328
T2 36 (41.9 %) 15 (35.7 %) 51 (39.8 %)
T3 31 (36.0 %) 22 (52.4 %) 53 (41.4 %)
T4 6 (7.0 %) 2 (4.8 %) 8 (6.2 %)
N-stage* Positive (N1-3) 57 (66.3 %) 39 (92.9 %) 96 (75.0 %) 0.001
M1 Positive (M1) 29 (33.7 %) 20 (47.6 %) 49 (38.3 %) 0.175
Grading* G1 6 (7.0 %) 0 (0) 6 (4.7 %) <0.001
G2 45 (52.3 %) 1 (2.4 %) 46 (35.9 %)
G3 35 (40.7 %) 41 (97.6 %) 76 (59.4 %)
Localisation* Cardia 30 (34.9 %) 6 (14.3 %) 36 (28.1 %) 0.042
Corpus 33 (38.4 %) 23 (54.8 %) 56 (43.8 %)
Antrum 23 (26.7 %) 13 (31.0 %) 36 (28.1 %)
Comparison between intestinal and diffuse type tumors was done by Fisher's exact test with significant differences (p < 0.05) marked by an asterisk. IQR:
interquartile range; Grading: G1: well differentiated, G2: moderately differentiated, G3: poorly differentiated
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(T3 and T4) compared to early disease (T1 and T2).
However, the immune-reactivity score for mTOR was
higher in the tumor center of patients with evidence of
distant metastases (p = 0.01), and MMP7 was more highly
expressed in the tumors of patients with nodal involve-
ment (tumor center: p = 0.01, invasive front: p = 0.019;
data not shown). Otherwise there was no association of
MMP staining with any tumor-associated parameter.
In a parallel proof-of-principle approach, we treated
MKN45 gastric cancer cells with rapamycin to investi-
gate the effect of mTOR inhibition on MMP expression.
Rapamycin treatment led to an effective inhibition of
mTOR signalling, mirrored by a reduction of p-
P70S6K, the main downstream target of mTOR signal-
ling (Additional file 5: Figure S4). Transcript levels of
MMP2, MMP7 and MMP9 were clearly expressed in
the cells at baseline and were not systematically af-
fected by mTOR inhibition, as assessed by RT-PCR
(data not shown).
To our knowledge, this is the first study that analyses
the association of the expression of three specific MMPs
and mTOR in its native and in its activated, phosphory-
lated form in human gastric cancer tissue. The expres-
sion pattern for MMP2 was consistent with previous
reports [14, 15]. Surprisingly, MMP7 showed higher
staining scores in the tumor center, but it must be taken
into account that we scored only positive staining within
the gastric cancer cells and not of stromal components
which can also express MMP7 [16]. Expression of
MMP2, MMP7 and MMP9 could be confirmed in the
majority of gastric cancers, but there was no significant
correlation with the presence of either mTOR or p-
mTOR. The association of MMP9 with mTOR was only
weak in intestinal type cancers, suggesting a probable
interaction of other regulatory mechanisms, such as
pathways that respond to inflammatory stimuli [11, 12,
17, 18]. There are further alternative mechanisms that
may interfere at this level such as MMP2 being capable
of activating MMP9 [19, 20]. In a previous study, MMP2
and MMP7 expression were reduced by the mTOR in-
hibitor rapamycin in human gastric NUGC4 cells that
have been stimulated with CXCL12 [21]. MKN45 cells
were chosen for this work because that are derived from
a poorly differentiated gastric cancer and express both
the respective MMPs and mTOR at baseline without the
need for stimulation or transfection. Since both mTOR
and the MMPs were expressed in MKN45 and the nega-
tive findings supported the IHC data showing no associ-
ation between mTOR and MMP expression in gastric
cancer no additional cell line validation was undertaken.
The lack of an association of mTOR signalling and
MMP expression might be due to the interplay with
pathways that are involved in regulation of mucosal in-
flammation which are dependent on the very complex
tissue microenvironment within gastric cancer. As men-
tioned above for MMP9, NFκB-dependent induction in
response to inflammatory stimuli has been reported [11,
17, 18, 20, 22, 23], and MMP9 expression is raised in
cag-dependent manner in the course of H. pylori infec-
tion. H. pylori induced inflammation can induce both
MMP9 and MMP7 expression in the gastric mucosa me-
diated by tissue macrophages [24–27]. Furthermore,
mTOR seems to have a stage-dependent impact, with
the expression being higher in earlier stages of gastric
carcinogenesis; however, our cohort mostly consisted of
advanced stage cancers.
It has been reported that expression and functional activ-
ity of both mTOR and specific MMPs are associated with
less favourable prognosis in gastric carcinoma, with overall
heterogeneous results and stronger evidence for mTOR [3,
7, 28–31]. None of the parameters analysed were associ-
ated with overall survival in our cohort (data not shown).
However, due to the retrospective nature of the study, sur-
vival data could not be gathered for all patients.
In summary, an association between the presence of
MMP2 and MMP7 proteins and (p-)mTOR expression
in gastric cancer could not be confirmed. A correlation
of MMP9 with mTOR expression in intestinal type can-
cers was only of weak character and doesn't support
mTOR as being the main regulating factor. Future stud-
ies should address alternative pathways and consider the
influence of the inflammatory microenvironment of the
surrounding mucosa.
Additional files
Additional file 1: (DOCX 25 kb)
Additional file 2: Figure S1. Relative expression of mTOR and MMPs.
Partition of samples with positive staining of mTOR, p-mTOR, MMP2,
MMP7 and MMP9 each at the tumor center and at the invasive front.
Comparison of both localisations have been done by Fisher's exact test.
Significant differences (p<0.05) are marked with an asterisk. (TIF 447 kb)
Additional file 3: Figure S2. Correlation of staining scores between
tumor center and invasive front. Displayed are the patient-matched
paired IRS for the staining reaction at the tumor center and the invasive
front for (a) MMP2, (b) MMP7, (c) MMP9, (d) mTOR and (e) p-mTOR.
Correlation of the IRS for tumor center and invasive front was done by
Spearman's rank correlation test with p<0.05 considered as significant.
(TIF 4658 kb)
Additional file 4: Figure S3. Correlation of staining scores between
different factors. Displayed are the patient-matched paired IRS for MMP9
and mTOR at the tumor center of intestinal type cancers (a), for mTOR
and p-mTOR at the tumor center (b), and for MMP2 and MMP9 at the
invasive front (c). Correlation analysis was done by Spearman's rank
correlation test with p<0.05 considered as significant. (TIF 1937 kb)
Additional file 5: Figure S4. mTOR inhibition by rapamycin in MKN45
gastric cancer cells. Western Blot of expression of p-P70S6K1, P70S6K1
and β-actin in MKN45 cells that have been treated with rapamycin (RAPA)
for each 24h, 48h and 72h (a). Corresponding results of the PCR analysis
of the transcript content MMP2, MMP7 and MMP9. There was no significant
effect on MMP expression by treatment with rapamycin. For MMP9 only as-
sessment after 48 hours gave consistent results. UC: untreated controls;
DMSO: treatment with DMSO only. (TIF 2341 kb)
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